2023年3月10日

波士頓和倫敦，2023年3月10日(GLOBE NEWSWIRE)——全球基因治療領導者Orchard Therapeutics (Nasdaq: ORTX)今天宣布，該公司此前披露的美國存托股票(“ADS”)與普通股比例的變化已經生效。比率已經從一股美國存托憑證與一股普通股的比率改變為一股美國存托憑證與十股普通股的比率。對於公司的ADS持有人來說，ADS比例的變化與ADS反向分割的十分之一具有相同的效果，旨在使公司重新符合納斯達克的最低投標價格要求。在比例變化生效時，當時持有的所有美國存托憑證均被注銷，並發行新的美國存托憑證，即每注銷10隻美國存托憑證，就發行1隻美國存托憑證。未認證的美國存托憑證持有人自動交換其美國存托憑證。ADS比率的變化對Orchard的基礎普通股沒有影響，並且不會因ADS比率的變化而發行或取消普通股。該比率變動將統一影響所有股東，且不會改變任何股東在公司股權中的百分比權益，除非該比率變動將導致股東擁有部分美國存托憑證。在比率變化中，沒有部分ads發行。相反，新存托憑證的部分權益將由存托銀行彙總並出售，出售所得的淨現金收入(扣除費用、稅收和開支後)將由存托銀行分配給適用的存托憑證持有人。Orchard的美國存托憑證繼續在納斯達克資本市場交易，股票代碼為“ORTX”。 About Orchard Therapeutics At Orchard Therapeutics, our vision is to end the devastation caused by genetic and other severe diseases. We aim to do this by discovering, developing and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease in a single treatment. In 2018, the company acquired GSK’s rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Today, Orchard is advancing a pipeline spanning pre-clinical, clinical and commercial stage HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist. Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit www.orchard-tx.com , and follow us on Twitter and LinkedIn . Availability of Other Information About Orchard Investors and others should note that Orchard communicates with its investors and the public using the company website ( www.orchard-tx.com ), the investor relations website ( ir.orchard-tx.com ), and on social media ( Twitter and LinkedIn ), including but not limited to investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchard’s investor relations website and may include additional social media channels. The contents of Orchard’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. Contacts